Roche PS

In a registration-relevant head-to-head trial against Lumakras (Amgen) and Krazati (Mirati Therapeutics), Divarasib achieved significant improvements in progression-free survival and overall survival. No new safety signals were observed. Roche plans to submit the data to regulators and present the results at a medical congress. » Mais em finanzen.net

The FDA has accepted the approval application for Roche's drug candidate Giredestrant for review. This brings a potential U.S. approval for Giredestrant one step closer. Further regulatory steps and decisions remain pending. » Mais em finanzen.net

Roche has announced the release of new data from its obesity portfolio. Details on study results or timelines were not mentioned in the text, and investors are awaiting further information on the efficacy and regulatory approval prospects of the treatments. » Mais em finanzen.net